Advanced bioprinting biomaterials for personalized cancer therapy and drug screening: From functional bioinks to precision oncology platforms
Three-dimensional (3D) bioprinting is increasingly used to construct patient-relevant tumor models, but its value for precision oncology depends on how functional biomaterials connect tissue reconstruction with therapeutic exposure and response measurement. This review presents a function-oriented framework for advanced bioprinting biomaterials in personalized cancer therapy and drug screening. We define functional biomaterials as printable or print-compatible systems that actively regulate cellular behavior, extracellular-matrix cues, transport, release, microenvironmental adaptation, or response reporting, while distinguishing them from patient-derived biological inputs and enabling technologies. We examine how bioink composition, crosslinking, mechanics, degradation, and spatial patterning influence tumor heterogeneity, stromal interactions, vascular, immune, and hypoxic niches, and therapeutic transport. Particular attention is given to localized drug delivery, nanocomposite and stimuli-responsive systems, sequential exposure, and quantitative evaluation of drug distribution and response. Two representative platforms illustrate how material design can couple microenvironment reconstruction with chemoradiotherapy, chemotherapy, and chimeric antigen receptor-T cell response testing. We also assess patient-derived tumor models for personalized drug testing, including model establishment, heterogeneity preservation, assay reproducibility, and the relationship between ex vivo response and clinical decision-making. Bioink-selection principles and study-level reporting benchmarks are summarized without pooling non-equivalent metrics. Finally, we discuss sample attrition, turnaround time, cost, manufacturing variability, quality control, interlaboratory reproducibility, clinical validation, and regulatory requirements. Clinically useful platforms will be those in which each functional component addresses a defined biological or therapeutic question and generates reproducible, interpretable information, rather than those with the greatest material or architectural complexity.
- Abuwatfa WH, Pitt WG, Husseini GA. Scaffold-based 3D cell culture models in cancer research. J Biomed Sci. 2024;31(1):7. doi: 10.1186/s12929-024-00994-y
- Jung M, Ghamrawi S, Du EY, Gooding JJ, Kavallaris M. Advances in 3D bioprinting for cancer biology and precision medicine: from matrix design to application. Adv Healthc Mater. 2022;11(24):2200690. doi: 10.1002/adhm.202200690
- Huang Z, Duan X, Ji J, et al. Deconstructing cancer in 3D: models, mechanisms, and personalized solutions. Mol Cancer. 2026;25(1):195. doi: 10.1186/s12943-026-02704-8
- Shukla P, Yeleswarapu S, Heinrich MA, Prakash J, Pati F. Mimicking tumor microenvironment by 3D bioprinting: 3D cancer modeling. Biofabrication. 2022;14(3):032002. doi: 10.1088/1758-5090/ac6d11
- Branco F, Cunha J, Mendes M, Sousa JOJ, Vitorino C. 3D bioprinting models for glioblastoma: from scaffold design to therapeutic application. Adv Mater. 2025;37(18):2501994. doi: 10.1002/adma.202501994
- Lv J, Du X, Wang M, Su J, Wei Y, Xu C. Construction of tumor organoids and their application to cancer research and therapy. Theranostics. 2024;14(3):1101-1125. doi: 10.7150/thno.91362
- Dong Y, Zhou X, Ding Y, Luo Y, Zhao H. Advances in tumor microenvironment: applications and challenges of 3D bioprinting. Biochem Biophys Res Commun. 2024;730:150339. doi: 10.1016/j.bbrc.2024.150339
- Yang Y, Kong Y, Cui J, Hou Y, Gu Z, Ma C. Advances and applications of cancer organoids in drug screening and personalized medicine. Stem Cell Rev Rep. 2024;20(5):1213-1226. doi: 10.1007/s12015-024-10714-6
- Arani RM, Yousefi N, Hamidieh AA, Gholizadeh F, Sisakht MM. Tumor organoid as a drug screening platform for cancer research. Curr Stem Cell Res Ther. 2024;19(9):1210-1250. doi: 10.2174/011574888X268366230922080423
- Yang J, Wang L, Wu R, et al. 3D Bioprinting in Cancer Modeling and Biomedicine: From Print Categories to Biological Applications. ACS Omega. 2024;9(44):44076-44100. doi: 10.1021/acsomega.4c06051
- Qu J, Kalyani FS, Liu L, Cheng T, Chen L. Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy. Cancer Commun (Lond). 2021;41(12):1331-1353. doi: 10.1002/cac2.12224
- Wang Y, Zhang L, Wang LZ, et al. The application of organoids in treatment decision-making for digestive system cancers: progress and challenges. Mol Cancer. 2025;24(1):222. doi: 10.1186/s12943-025-02429-0
- Banerjee D, Singh YP, Datta P, et al. Strategies for 3D bioprinting of spheroids: A comprehensive review. Biomaterials. 2022;291:121881. doi: 10.1016/j.biomaterials.2022.121881
- Li Y, Liu J, Xu S, Wang J. 3D Bioprinting: An Important Tool for Tumor Microenvironment Research. Int J Nanomedicine. 2023;18:8039-8057. doi: 10.2147/IJN.S435845
- Wang X, Luo Y, Ma Y, Wang P, Yao R. Converging bioprinting and organoids to better recapitulate the tumor microenvironment. Trends Biotechnol. 2024;42(5):648-663. doi: 10.1016/j.tibtech.2023.11.006
- Xie R, Yang J, Lu X, et al. Physiologically relevant 3D tumor models for therapeutic screening. Biomaterials. 2026;334:124231. doi: 10.1016/j.biomaterials.2026.124231
- Mazzaglia C, Shery Huang YY, Shields JD. Advancing tumor microenvironment and lymphoid tissue research through 3D bioprinting and biofabrication. Adv Drug Deliv Rev. 2025;217:115485. doi: 10.1016/j.addr.2024.115485
- de Barros NR, Gomez A, Ermis M, et al. Gelatin methacryloyl and laponite bioink for 3D bioprinted organotypic tumor modeling. Biofabrication. 2023;15(4):045005. doi: 10.1088/1758-5090/ace0db
- Chakraborty A, Roy A, Ravi SP, Paul A. Exploiting the role of nanoparticles for use in hydrogel-based bioprinting applications: concept, design, and recent advances. Biomater Sci. 2021;9(19):6337-6354. doi: 10.1039/D1BM00605C
- Fernandes PD, Silva FC, Magalhães FOD, Pereira RBF, Santos SG, Pinto AM. 3D printing of nanoparticle-containing scaffolds for cancer phototherapy, magnetic hyperthermia therapy, and tissue regeneration. Acta Biomater. 2026;210:221-279. doi: 10.1016/j.actbio.2025.11.043
- Iyer KS, Bao L, Zhai J, et al. Microgel-based bioink for extrusion-based 3D bioprinting and its applications in tissue engineering. Bioact Mater. 2025;48:273-293. doi: 10.1016/j.bioactmat.2025.02.003
- Hull SM, Lou J, Lindsay CD, et al. 3D bioprinting of dynamic hydrogel bioinks enabled by small molecule modulators. Sci Adv. 2023;9(13):eade7880. doi: 10.1126/sciadv.ade7880
- Zhang C, Shen Y, Huang M, et al. Dynamic hydrogel mechanics in organoid engineering: from matrix design to translational paradigms. Bioact Mater. 2026;55:144-170. doi: 10.1016/j.bioactmat.2025.09.021
- Wang Y, Duan Y, Yang B, Li Y. Nanocomposite hydrogel bioinks for 3D bioprinting of tumor models. Biomacromolecules. 2024;25(8):5288-5299. doi: 10.1021/acs.biomac.4c00671
- Jeong W, Kim D, Wajih N, et al. The effect of stiffness on cell behavior and drug resistance in patient-derived breast cancer organoids. Acta Biomater. 2026;210:27-39. doi: 10.1016/j.actbio.2025.12.026
- Blanco-Fernandez B, Bagci G, Perez-Amodio S, et al. A bioprinted breast cancer model using bioinks of decellularized breast tissue for studying cancer stemness, invasion, and drug efficacy. Acta Biomater. 2025;203:306-321. doi: 10.1016/j.actbio.2025.07.054
- Yang R, Yu Y. Patient-derived organoids in translational oncology and drug screening. Cancer Lett. 2023;562:216180. doi: 10.1016/j.canlet.2023.216180
- Fang T, Cao X, Ibnat M, Chen G. Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing. J Nanobiotechnology. 2022;20(1):354. doi: 10.1186/s12951-022-01570-y
- Wei D, Sun Y, Zhu H, Fu Q. Stimuli-Responsive Polymer-Based Nanosystems for Cancer Theranostics. ACS Nano. 2023;17(23):23223-23261. doi: 10.1021/acsnano.3c06019
- Vaskovich-Koubi D, Green Buzhor M, Krinsky A, et al. Patient-derived 3D-bioprinted models of pancreatic cancer: toward personalized therapy and overcoming tumor microenvironment challenges. Adv Drug Deliv Rev. 2025;225:115670. doi: 10.1016/j.addr.2025.115670
- Jung M, Poltavets V, Skhinas JN, et al. High-throughput 3D engineered paediatric tumour models for precision medicine. Mol Syst Biol. 2025;21(12):1748-1777. doi: 10.1038/s44320-025-00152-y
- Li M, Freeman S, Franco-Barraza J, et al. A bioprinted sea-and-island multicellular model for dissecting human pancreatic tumor-stroma reciprocity and adaptive metabolism. Biomaterials. 2024;310:122631. doi: 10.1016/j.biomaterials.2024.122631
- Han J, Jeong HJ, Choi J, et al. Bioprinted patient-derived organoid arrays capture intrinsic and extrinsic tumor features for advanced personalized medicine. Adv Sci (Weinh). 2025;12(20):2407871. doi: 10.1002/advs.202407871
- Chen H, Wu Z, Gong Z, et al. Acoustic bioprinting of patient-derived organoids for predicting cancer therapy responses. Adv Healthc Mater. 2022;11(13):e2102784. doi: 10.1002/adhm.202102784
- Du L, Zheng Z, Zhang K, et al. Exploring personalized prediction of clinical chemotherapy efficacy and revealing tumor heterogeneity using patient-derived 3D bioprinting gastric cancer models. Mol Cancer. 2025;24(1):259. doi: 10.1186/s12943-025-02466-9
- Yi HG, Jeong YH, Kim Y, et al. A bioprinted human-glioblastoma-on-a-chip for the identification of patient-specific responses to chemoradiotherapy. Nat Biomed Eng. 2019;3(7):509-519. doi: 10.1038/s41551-019-0363-x
- Dey M, Kim MH, Dogan M, et al. Chemotherapeutics and CAR-T Cell-Based Immunotherapeutics Screening on a 3D Bioprinted Vascularized Breast Tumor Model. Adv Funct Mater. 2022;32(52):2203966. doi: 10.1002/adfm.202203966
- Germain N, Dhayer M, Dekiouk S, Marchetti P. Current advances in 3D bioprinting for cancer modeling and personalized medicine. Int J Mol Sci. 2022;23(7):3432. doi: 10.3390/ijms23073432
- Yu J, Zhang Y, Ran R, et al. Research progress in the field of tumor model construction using bioprinting: a review. Int J Nanomedicine. 2024;19:6547-6575. doi: 10.2147/IJN.S460387
- Yao L, Xie P, Huang T, et al. 3D Bioprinting for Tumor Microenvironment Reconstruction: Advances, Challenges, and Future Perspectives. Biotechnol J. 2026;21(6):e70267. doi: 10.1002/biot.70267
- Parodi I, Di Lisa D, Pastorino L, Scaglione S, Fato MM. 3D bioprinting as a powerful technique for recreating the tumor microenvironment. Gels. 2023;9(6):482. doi: 10.3390/gels9060482
- Aoun J, de Oliveira H, Fennell S, Diab-Assaf M, Caldefie-Chezet F, Delort L. 3D bioprinting for reproducing the tumor microenvironment in cancer research models. Curr Res Biotechnol. 2026;11:100385. doi: 10.1016/j.crbiot.2026.100385
- Xu J, Yang S, Su Y, et al. A 3D bioprinted tumor model fabricated with gelatin/sodium alginate/decellularized extracellular matrix bioink. Int J Bioprint. 2022;9(1):630. doi: 10.18063/ijb.v9i1.630
- Wang H, Yu H, Zhou X, et al. An overview of extracellular matrix-based bioinks for 3D bioprinting. Front Bioeng Biotechnol. 2022;10:905438. doi: 10.3389/fbioe.2022.905438
- Chen Q, Zhou R, Xu Q, Li Z, Tao J. dECM bioinks for 3D bioprinted tumor models: Advances, challenges, and drug screening. iScience. 2026;29(8):117085. doi: 10.1016/j.isci.2026.117085
- Tiwari AP, Thorat ND, Pricl S, Patil RM, Rohiwal S, Townley H. Bioink: a 3D-bioprinting tool for anticancer drug discovery and cancer management. Drug Discov Today. 2021;26(7):1574-1590. doi: 10.1016/j.drudis.2021.03.010
- Xu H, Zhang S, Song K, Yang H, Yin J, Huang Y. Droplet-based 3D bioprinting for drug delivery and screening. Adv Drug Deliv Rev. 2025;217:115486. doi: 10.1016/j.addr.2024.115486
- Gillispie G, Prim P, Copus J, et al. Assessment methodologies for extrusion-based bioink printability. Biofabrication. 2020;12(2):022003. doi: 10.1088/1758-5090/ab6f0d
- Miri AK, Mirzaee I, Hassan S, et al. Effective bioprinting resolution in tissue model fabrication. Lab Chip. 2019;19(11):2019-2037. doi: 10.1039/C8LC01037D
- Murab S, Gupta A, Włodarczyk-Biegun MGK, et al. Alginate based hydrogel inks for 3D bioprinting of engineered orthopedic tissues. Carbohydr Polym. 2022;296:119964. doi: 10.1016/j.carbpol.2022.119964
- Ermis M, Falcone N, Roberto de Barros N, et al. Tunable hybrid hydrogels with multicellular spheroids for modeling desmoplastic pancreatic cancer. Bioact Mater. 2023;25:360-373. doi: 10.1016/j.bioactmat.2023.02.005
- Dai X, Liu L, Ouyang J, et al. Coaxial 3D bioprinting of self-assembled multicellular heterogeneous tumor fibers. Sci Rep. 2017;7(1):1457. doi: 10.1038/s41598-017-01581-y
- Gugulothu SB, Joseph JP, Chatterjee K. A 3D-bioprinted hydrogel platform with tunable matrix stiffness reveals mechanical adaptation and doxorubicin resistance in triple-negative breast cancer. J Mater Chem B. 2026;14(27):8460-8474. doi: 10.1039/d6tb00892e
- Kataki AD, Gupta PG, Cheema U, et al. Mapping tumor-stroma-ECM interactions in spatially advanced 3D models of pancreatic cancer. ACS Appl Mater Interfaces. 2025;17(11):16708-16724. doi: 10.1021/acsami.5c02296
- González-Callejo P, Vázquez-Aristizabal P, García-Astrain C, et al. 3D bioprinted breast tumor-stroma models for pre-clinical drug testing. Mater Today Bio. 2023;23:100826. doi: 10.1016/j.mtbio.2023.100826
- Yu IS, Li YCE, Chen PY, Chen KT, Lee IC. 3D bioprinted silk fibroin- and hyaluronic acid-based biomimetic extracellular matrices with tunable stiffness regulate glioblastoma invasion and macrophage polarization. Int J Biol Macromol. 2026;379:153883. doi: 10.1016/j.ijbiomac.2026.153883
- Choi YM, Na D, Yoon G, et al. Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient-Derived Tissue Laden Tissue-Specific Bioink. Adv Sci (Weinh). 2025;12(10):e2411769. doi: 10.1002/advs.202411769
- Shukla P, Bera AK, Yeleswarapu S, Pati F. High Throughput Bioprinting Using Decellularized Adipose Tissue-Based Hydrogels for 3D Breast Cancer Modeling. Macromol Biosci. 2024;24(8):e2400035. doi: 10.1002/mabi.202400035
- Devarasetty M, Mazzocchi AR, Skardal A. Applications of bioengineered 3D tissue and tumor organoids in drug development and precision medicine: current and future. BioDrugs. 2018;32(1):53-68. doi: 10.1007/s40259-017-0258-x
- Mierke CT. Bioprinting of cells, organoids and organs-on-a-chip together with hydrogels improves structural and mechanical cues. Cells. 2024;13(19):1638. doi: 10.3390/cells13191638
- Bidan NG, Dunsmore G, Ugrinic M, et al. Multicellular tumor spheroid model to study the multifaceted role of tumor-associated macrophages in PDAC. Drug Deliv Transl Res. 2024;14(8):2085-2099. doi: 10.1007/s13346-023-01479-5
- Ju M, Jin Z, Yu X, et al. Gastric Cancer Models Developed via GelMA 3D Bioprinting Accurately Mimic Cancer Hallmarks, Tumor Microenvironment Features, and Drug Responses. Small. 2025;21(8):e2409321. doi: 10.1002/smll.202409321
- Immohr MB, Dos Santos Adrego F, Teichert HL, et al. 3D-bioprinting of aortic valve interstitial cells: impact of hydrogel and printing parameters on cell viability. Biomed Mater. 2023;18(1):015004. doi: 10.1088/1748-605X/ac9f91
- Chang TW, Huang MW, Dong GC, Lee IC. Construction of a 3D bioprinted microfluidic platform to study breast cancer bone metastasis and tumor microenvironmental influences. ACS Appl Mater Interfaces. 2025;17(45):61718-61730. doi: 10.1021/acsami.5c15529
- Li J, Parra-Cantu C, Wang Z, Zhang YS. Improving bioprinted volumetric tumor microenvironments In vitro. Trends Cancer. 2020;6(9):745-756. doi: 10.1016/j.trecan.2020.06.002
- Bilotta MT, Antignani A, Fitzgerald DJ. Managing the TME to improve the efficacy of cancer therapy. Front Immunol. 2022;13:954992. doi: 10.3389/fimmu.2022.954992
- Zhou B, Sun M, Yang M, Cui W, Yang H. Construction and application of multicellular tumor microenvironment models based on three-dimensional bioprinting technology. Hepatobiliary Surg Nutr. 2025;14(4):692-696. doi: 10.21037/hbsn-2025-504
- Wu Y, Zhang F, Du F, Huang J, Wei S. Combination of tumor organoids with advanced technologies: a powerful platform for tumor evolution and treatment response (review). Mol Med Rep. 2025;31(6):140. doi: 10.3892/mmr.2025.13505
- Bocheng X, França R. Innovative 3D bioprinting approaches for advancing brain science and medicine: a literature review. Biomed Phys Eng Express. 2024;10(6):062002. doi: 10.1088/2057-1976/ad795c
- Choi J, Lee EJ, Jang WB, Kwon SM. Development of biocompatible 3D-printed artificial blood vessels through multidimensional approaches. J Funct Biomater. 2023;14(10):497. doi: 10.3390/jfb14100497
- Albritton JL, Miller JS. 3D bioprinting: improving in vitro models of metastasis with heterogeneous tumor microenvironments. Dis Model Mech. 2017;10(1):3-14. doi: 10.1242/dmm.025049
- Bertassoni LE. Bioprinting of complex multicellular organs with advanced functionality—recent progress and challenges ahead. Adv Mater. 2022;34(3):2101321. doi: 10.1002/adma.202101321
- Tayler IM, Stowers RS. Engineering hydrogels for personalized disease modeling and regenerative medicine. Acta Biomater. 2021;132:4-22. doi: 10.1016/j.actbio.2021.04.020
- Plava J, Cehakova M, Kuniakova M, et al. The third dimension of tumor microenvironment—the importance of tumor stroma in 3D cancer models. Exp Biol Med (Maywood). 2023;248(15):1347-1358. doi: 10.1177/15353702231198050
- Pedron S, Wolter GL, Chen JWE, Laken SE, Sarkaria JN, Harley BAC. Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens. Biomaterials. 2019;219:119371. doi: 10.1016/j.biomaterials.2019.119371
- Domingues MF, Carreira MC, Santos MS, et al. A 3D Bioprinted Spheroid-Laden dECM-Enriched Osteosarcoma Model for Enhanced Drug Testing and Therapeutic Discovery. Adv Healthc Mater. 2026;15(15):e03633. doi: 10.1002/adhm.202503633
- An S, Jo S, Kim G. A mechanobiology-driven cell-derived ECM bioink for engineering 3D glioblastoma tumor microenvironment models. Theranostics. 2026;16(14):8361-8384. doi: 10.7150/thno.137729
- Stecher S, Schenk J, Cianciosi A, et al. 3D Bioprinted Breast Cancer-Stroma Model with Tailored Migration-Permissive Bioink Reveals Impact of Adipose-Derived Stromal Cells on Cancer Cell Migration and Invasion Dynamics. Adv Healthc Mater. 2026;15(30):e71353. doi: 10.1002/adhm.71353
- Chen Y, Xue Y, Yan C, et al. Bioprinted Fibroblast Mediated Heterogeneous Tumor Microenvironment for Studying Tumor-Stroma Interaction and Drug Screening. Adv Healthc Mater. 2025;14(7):e2404642. doi: 10.1002/adhm.202404642
- Xu K, Huang Y, Wu M, Yin J, Wei P. 3D bioprinting of multi-cellular tumor microenvironment for prostate cancer metastasis. Biofabrication. 2023;15(3):035020. doi: 10.1088/1758-5090/acd960
- Rasti Boroojeni F, Naeimipour S, Lifwergren P, et al. Proteolytic remodeling of 3D bioprinted tumor microenvironments. Biofabrication. 2024;16(2):025002. doi: 10.1088/1758-5090/ad17d1
- Desigaux T, Comperat L, Dusserre N, et al. 3D bioprinted breast cancer model reveals stroma-mediated modulation of extracellular matrix and radiosensitivity. Bioact Mater. 2024;42:316-327. doi: 10.1016/j.bioactmat.2024.08.037
- Krajewska U, Chechlińska M, Kurzyk A. Vascularisation in 3D bioprinted models: emerging solutions engineering functional tissues and tumour models. Biofabrication. 2026;18(2):022001. doi: 10.1088/1758-5090/ae2f02
- Zhao Y, Peng Y, Hu R, et al. Seamless vessel-microenvironment bioprinting reveals contact-dependent vascular communications. Trends Biotechnol. 2026;44(7):2140-2169. doi: 10.1016/j.tibtech.2026.02.003
- Gao Q, Guo Z, Zhang S, et al. Coaxial bioprinting of microsphere bioink to engineer heterogeneous vascularized lung cancer model. Biomater Adv. 2026;183:214741. doi: 10.1016/j.bioadv.2026.214741
- Neufeld L, Yeini E, Reisman N, et al. Microengineered perfusable 3D-bioprinted glioblastoma model for in vivo mimicry of tumor microenvironment. Sci Adv. 2021;7(34):eabi9119. doi: 10.1126/sciadv.abi9119
- Grunewald L, Lam T, Andersch L, et al. A reproducible bioprinted 3D tumor model serves as a preselection tool for CAR T cell therapy optimization. Front Immunol. 2021;12:689697. doi: 10.3389/fimmu.2021.689697
- Tang M, Xie Q, Gimple RC, et al. Three-dimensional bioprinted glioblastoma microenvironments model cellular dependencies and immune interactions. Cell Res. 2020;30(10):833-853. doi: 10.1038/s41422-020-0338-1
- Zimmer J, Castriconi R, Scaglione S. Editorial: recent 3D tumor models for testing immune-mediated therapies. Front Immunol. 2021;12:798493. doi: 10.3389/fimmu.2021.798493
- Naoi Y, Inukai Y, Izumikawa T, et al. Close Spatial Interactions between Cancer Cells and Cancer-Associated Fibroblasts Suppress Antitumor Immunity. Cancer Immunol Res. 2025;13(9):1471-1484. doi: 10.1158/2326-6066.cir-24-1144
- Andersch L, Grunewald L, Stecklum M, et al. Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model. Front Immunol. 2025;16:1677361. doi: 10.3389/fimmu.2025.1677361
- Sun X, Zhang Z, Zhao W, et al. Prediction of CAR-T Therapy In Vitro: Development of Biomimetic Models for CAR-T Killing Effect Assessment. Small. 2025;21(37):e2503384. doi: 10.1002/smll.202503384
- Kim D, Jo S, Lee D, et al. NK cells encapsulated in micro/macropore-forming hydrogels via 3D bioprinting for tumor immunotherapy. Biomater Res. 2023;27(1):60. doi: 10.1186/s40824-023-00403-9
- Morley CD, Flores CT, Drake JA, Moore GL, Mitchell DA, Angelini TE. Spatiotemporal T cell dynamics in a 3D bioprinted immunotherapy model. Bioprinting. 2022;28:e00231. doi: 10.1016/j.bprint.2022.e00231
- Heinrich MA, Bansal R, Lammers T, Zhang YS, Michel Schiffelers R, Prakash J. 3D-bioprinted mini-brain: a glioblastoma model to study cellular interactions and therapeutics. Adv Mater. 2019;31(14):e1806590. doi: 10.1002/adma.201806590
- Tung YT, Chen YC, Derr K, Wilson K, Song MJ, Ferrer M. A 3D Bioprinted Human Neurovascular Unit Model of Glioblastoma Tumor Growth. Adv Healthc Mater. 2024;13(15):e2302831. doi: 10.1002/adhm.202302831
- Yao EJ, Lu GY, Vadla R, et al. Forming a Precise and Reproducible Hypoxic Tumor Microenvironment in Glioblastoma by High Cell Density Bioprinting. Adv Healthc Mater. 2026;15(26):e71322. doi: 10.1002/adhm.71322
- Wang X, Yang X, Liu Z, et al. 3D bioprinting of an in vitro hepatoma microenvironment model: Establishment, evaluation, and anticancer drug testing. Acta Biomater. 2024;185:173-189. doi: 10.1016/j.actbio.2024.07.019
- Devarasetty M, Wang E, Soker S, Skardal A. Mesenchymal stem cells support growth and organization of host-liver colorectal-tumor organoids and possibly resistance to chemotherapy. Biofabrication. 2017;9(2):021002. doi: 10.1088/1758-5090/aa7484
- Zhang Z, Chen X, Gao S, Fang X, Ren S. 3D bioprinted tumor model: a prompt and convenient platform for overcoming immunotherapy resistance by recapitulating the tumor microenvironment. Cell Oncol (Dordr). 2024;47(4):1113-1126. doi: 10.1007/s13402-024-00935-9
- Kim D, Jo S, Jang I, et al. Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR-NK Therapeutic Strategies. Adv Sci (Weinh). 2026;13(36):e202521188. doi: 10.1002/advs.202521188
- Wang P, Sun L, Li C, et al. Study on drug screening multicellular model for colorectal cancer constructed by three-dimensional bioprinting technology. Int J Bioprint. 2023;9(3):694. doi: 10.18063/ijb.694
- Ozturk MS, Lee VK, Zou H, Friedel RH, Intes X, Dai G. High-resolution tomographic analysis of in vitro 3D glioblastoma tumor model under long-term drug treatment. Sci Adv. 2020;6(10):eaay7513. doi: 10.1126/sciadv.aay7513
- Liu C, Shi C, Wang S, et al. Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine. Front Cell Dev Biol. 2025;13:1554268. doi: 10.3389/fcell.2025.1554268
- Uwimana A, Gnecco G, Riccaboni M. Artificial intelligence for breast cancer detection and its health technology assessment: a scoping review. Comput Biol Med. 2025;184:109391. doi: 10.1016/j.compbiomed.2024.109391
- Chen H, Zhang B, Huang J. Recent advances and applications of artificial intelligence in 3D bioprinting. Biophys Rev. 2024;5(3):031301. doi: 10.1063/5.0190208
- Wang J, Wang F, Jiang Y, Bai L, Chen X, Su J. Organoid-driven nanomedicine platform development. Biomaterials. 2026;325:123611. doi: 10.1016/j.biomaterials.2025.123611
- Shboul SA, DeLuca VJ, Dweiri YA, Saleh T. Can 3D bioprinting solve the mystery of senescence in cancer therapy? Ageing Res Rev. 2022;81:101732. doi: 10.1016/j.arr.2022.101732
- Masoumi Shahrbabak S, Jalali SM, Fathabadi MF, et al. Modified alginates for precision drug delivery: Advances in controlled-release and targeting systems. Int J Pharm X. 2025;10:100381. doi: 10.1016/j.ijpx.2025.100381
- Fu Y, Bian X, Li P, Huang Y, Li C. Carrier-Free Nanomedicine for Cancer Immunotherapy. J Biomed Nanotechnol. 2022;18(4):939-956. doi: 10.1166/jbn.2022.3315
- Liu JY, Zheng YY, Wang SY, et al. Advances in carrier-free nanodrug delivery systems. Drug Deliv Transl Res. 2026;16(8):2603-2621. doi: 10.1007/s13346-026-02118-5
- An J, Zhang Z, Zhang J, Zhang L, Liang G. Research progress in tumor therapy of carrier-free nanodrug. Biomed Pharmacother. 2024;178:117258. doi: 10.1016/j.biopha.2024.117258
- Zhang X, Hu S, Huang L, et al. Advance Progress in Assembly Mechanisms of Carrier-Free Nanodrugs for Cancer Treatment. Molecules. 2023;28(20):7065. doi: 10.3390/molecules28207065
- Guo Q, Lai L, Huang L, et al. Microfluidic fabrication of peptide modified carrier-free self-assembled crizotinib-metal nanodrugs for NIR fluorescence imaging and dual-pathway therapy of non-small cell lung cancer. J Colloid Interface Sci. 2026;711:140086. doi: 10.1016/j.jcis.2026.140086
- Fu N, Guo L, Zhou S, et al. Cinnamaldehyde-Based Self-Assembled Nanodrugs with GSH Depletion for Antitumor through Photodynamic Therapy Enhanced Ferroptosis and Immunotherapy. ACS Appl Mater Interfaces. 2026;18(14):20247-20264. doi: 10.1021/acsami.6c01928
- Zhao H, Yang C, Bao S, et al. Fe3+ loaded mastoparan M - ICG nanoassemblies for synergistic breast cancer therapy via photothermal and chemodynamic therapy-assisted oxidation stress. iScience. 2026;29(8):116740. doi: 10.1016/j.isci.2026.116740
- Cai S, Zhao J, Liu H, et al. Near-infrared light-triggered, self-amplifying targeted drug-delivery platform achieves precision treatment of retinoblastoma. Int J Pharm. 2026;701:127076. doi: 10.1016/j.ijpharm.2026.127076
- Troncoso-Afonso L, Vázquez-Aristizabal P, Vinnacombe-Willson GA, et al. dECM-Supported Printing of Plasmonic Pillars for SERS Monitoring of Chemotherapy in 3D Tumor Models. ACS Sens. 2025;10(9):7114-7123. doi: 10.1021/acssensors.5c02344
- Shahpouri M, Adili-Aghdam MA, Mahmudi H, et al. Prospects for hypoxia-based drug delivery platforms for the elimination of advanced metastatic tumors: From 3D modeling to clinical concepts. J Control Release. 2023;353:1002-1022. doi: 10.1016/j.jconrel.2022.12.009
- Zhang J, Luo X, Sun Z, Jin B, Zhao Y. Tumor Assembloids as Three-Dimensional Platforms for Modeling Drug Delivery Barriers: Construction Strategies, Applications, and Translational Challenges. Drug Des Devel Ther. 2026;20:1-16. doi: 10.2147/dddt.s618870
- Ingber DE. Human organs-on-chips for disease modelling, drug development and personalized medicine. Nat Rev Genet. 2022;23(8):467-491. doi: 10.1038/s41576-022-00466-9
- Marx U. Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development. ALTEX. 2020;37(3):365-394. doi: 10.14573/altex.2001241
- Herranz-Ors C, Bhosle SG, Beck AE, et al. A tumour-derived organoid biobank maps cancer gene dependencies. Nature. 2026;657(8132):765-774. doi: 10.1038/s41586-026-10830-y
- Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022;40(1):26-35. doi: 10.1016/j.ccell.2021.12.004
- Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920-926. doi: 10.1126/science.aao2774
- Maloney E, Clark C, Sivakumar H, et al. Immersion bioprinting of tumor organoids in multi-well plates for increasing chemotherapy screening throughput. Micromachines (Basel). 2020;11(2):208. doi: 10.3390/mi11020208
- Yang R, Wang S, Li Z, Yin C, Huang W, Huang W. Patient-derived organoid co-culture systems as next-generation models for bladder cancer stem cell research. Cancer Lett. 2025;625:217793. doi: 10.1016/j.canlet.2025.217793
- Liu B, Cheng H, Yu K, et al. Biomimetic 3D-Bioprinted organoids of thymic epithelial tumors for translational drug screening and biomarker identification. Mater Today Bio. 2026;37:102878. doi: 10.1016/j.mtbio.2026.102878
- Zhao Y, Li Y, Zhang W, et al. 3D-bioprinted liver cancer models derived from primary hepatocytes for simulating cancer initiation and drug screening. Hepatol Commun. 2025;9(11):e0823. doi: 10.1097/hc9.0000000000000823
- Rizwan M, Mei X, Cai L, et al. A 3D-bioprinted head and neck cancer model for drug screening. Biomed Mater. 2026;21(4):045004. doi: 10.1088/1748-605x/ae8069
- Kremneva E, Smolander J, Peltokangas M, et al. Precision tumor-on-chip for personalized assessment of drug efficacy and immune cell delivery. Cell Rep Methods. 2026;6(8):101475. doi: 10.1016/j.crmeth.2026.101475
- Tong F, Nie R, Wu Z, et al. Construction of 3D bioprinted colorectal cancer models and evaluation of their efficacy and drug sensitivity. APL Bioeng. 2026;10(3):036101. doi: 10.1063/5.0320497
- Tang M, Jiang S, Huang X, et al. Integration of 3D bioprinting and multi-algorithm machine learning identified glioma susceptibilities and microenvironment characteristics. Cell Discov. 2024;10(1):39. doi: 10.1038/s41421-024-00650-7
- Diosdi A, Toth T, Harmati M, et al. HCS-3DX, a next-generation AI-driven automated 3D-oid high-content screening system. Nat Commun. 2025;16(1):8897. doi: 10.1038/s41467-025-63955-5
- Becceneri AB, Liu S, Yildirim S, et al. Advancing photocytotoxicity evaluation of nitric oxide derivative-ruthenium complex in 3D biofabricated breast cancer models. Mater Today Bio. 2026;39:103348. doi: 10.1016/j.mtbio.2026.103348
- Scrocciolani C, Caserio L, Grillo S, et al. 3D Bioprinting of High-Grade Serous Ovarian Cancer Cells: Workflow for Gelatin-Based Bioink Formulation with Hyaluronic Acid and Printability Assessment. ACS Appl Bio Mater. 2026;9(14):6370-6387. doi: 10.1021/acsabm.6c00299
- Kirac MK, Bilge B, Ozdil CC, Tugcu T, Ulgen KO. 3D bioprinted melanoma constructs reveal delivery-dependent efficacy of phytochemical-gold nanoparticle formulations. Biomed Mater. 2026;21(3):035004. doi: 10.1088/1748-605x/ae5ee7
- Xu K, Wu J, Li Z, Chen W, Wei P, Wu M. The application of 3D cell culture for melanoma in vitro models. Acta Biomater. 2026;209:148-166. doi: 10.1016/j.actbio.2025.11.039
- Kim GM, Lee Y, Park S, Kim I, Lee HR, Jung S. 3-Layer lung cancer invasion model for evaluating MMP-targeted anti-metastatic therapeutics. Biomed Mater. 2026. doi: 10.1088/1748-605x/ae834f
- Si W, Zhou J, Jiang M. Lung cancer organoids for functional precision oncology: from disease modeling to clinical decision support. Front Oncol. 2026;16:1864153. doi: 10.3389/fonc.2026.1864153
- Majumder R, Datta P, Moolayadukkam S, Puri IK. Repurposing Alzheimer's and ovarian cancer drugs as sonosensitizers for glioblastoma via a positive-unlabeled learning and 3D bioprinting-based new approach methodology (NAM). PLoS One. 2026;21(8):e0354981. doi: 10.1371/journal.pone.0354981
- du Plessis J, Omar A. Patient-Derived Organoid-Based CRISPR Screens in Cancer Research: Applications, Advances, and Challenges. Cancer Med. 2026;15(8):e72112. doi: 10.1002/cam4.72112
- Mao S, Xie R, Shou J, Pang Y, Sun W. Bioprinting of patient-derived heterogeneous renal cell carcinoma organoids for personalized therapy. Biofabrication. 2025;17(4):045012. doi: 10.1088/1758-5090/adecc5
- Dai R, Chen W, Chen Y, et al. 3D bioprinting platform development for high-throughput cancer organoid models construction and drug evaluation. Biofabrication. 2024;16(3):035012. doi: 10.1088/1758-5090/ad51a6
- Mazzocchi A, Soker S, Skardal A. 3D bioprinting for high-throughput screening: drug screening, disease modeling, and precision medicine applications. Appl Phys Rev. 2019;6(1):011302. doi: 10.1063/1.5056188
- Xia Y, Chen H, Li J, et al. Acoustic Droplet-Assisted Superhydrophilic-Superhydrophobic Microarray Platform for High-Throughput Screening of Patient-Derived Tumor Spheroids. ACS Appl Mater Interfaces. 2021;13(20):23489-23501. doi: 10.1021/acsami.1c06655
- Ali ASM, Wu D, Bannach-Brown A, et al. 3D bioprinting of liver models: a systematic scoping review of methods, bioinks, and reporting quality. Mater Today Bio. 2024;26:100991. doi: 10.1016/j.mtbio.2024.100991
- Grijalva Garces D, Strauß S, Gretzinger S, et al. On the reproducibility of extrusion-based bioprinting: round robin study on standardization in the field. Biofabrication. 2024;16(1):015002. doi: 10.1088/1758-5090/acfe3b
- Agarwal T, Onesto V, Banerjee D, et al. 3D bioprinting in tissue engineering: current state-of-the-art and challenges towards system standardization and clinical translation. Biofabrication. 2025;17(4):042003. doi: 10.1088/1758-5090/ade47a
- Yang K, Wang L, Vijayavenkataraman S, Yuan Y, Tan ECK, Kang L. Recent applications of three-dimensional bioprinting in drug discovery and development. Adv Drug Deliv Rev. 2024;214:115456. doi: 10.1016/j.addr.2024.115456
- Zhang Y, Huang Z, Wang B, Li B, Yang Y. Three-dimensional bioprinted organoids: advances and clinical translation. Regen Biomater. 2026;13:rbag142. doi: 10.1093/rb/rbag142
- Li Y, Shi J, Zhang Q, Huang H, Zhou S. Three-Dimensional Bioprinting-Enabled Organoids for Engineering the Tumor Microenvironment. Tissue Eng Part B Rev. 2026. doi: 10.1177/19373368261469463
- Michael B, Jayaprakash N, Munivel N, Jaisankar D. 3D printing in drug delivery: emerging technologies, clinical translation, and the future of personalized medicine. Med Drug Discov. 2026;29:100242. doi: 10.1016/j.medidd.2025.100242
- Piotrowska U, Tsoi J, Singh P, Banerjee A, Sobczak M. 3D bioprinting and artificial intelligence for tumor microenvironment modeling: a scoping review of models, methods, and integration pathways. Mol Pharm. 2025;22(10):5801-5823. doi: 10.1021/acs.molpharmaceut.5c01062
- Zhang Z, Zhou X, Fang Y, Xiong Z, Zhang T. AI-driven 3D bioprinting for regenerative medicine: from bench to bedside. Bioact Mater. 2025;45:201-230. doi: 10.1016/j.bioactmat.2024.11.021
- Jaiswal C, Dey S, Prasad J, Gupta R, Agarwala M, Mandal BB. 3D bioprinted microfluidic based osteosarcoma-on-a chip model as a physiomimetic pre-clinical drug testing platform for anti-cancer drugs. Biomaterials. 2025;320:123267. doi: 10.1016/j.biomaterials.2025.123267
- Zhang C, Yang J, Xiao X, Yu W, Cai X. Spatial architecture and dynamic surveillance: 3D bioprinting and microfluidics converge to overcome digestive malignancies. Hepatobiliary Surg Nutr. 2026;15(4):115. doi: 10.21037/hbsn-2026-0598
- Strepi K, Koppenol RF, Jonkers J, Houthuijzen JM. Beyond the traditional dish: Advanced 3D ex vivo culture platforms for tumor modelling. Semin Cancer Biol. 2026;125:62-74. doi: 10.1016/j.semcancer.2026.07.002
- Murucci MD, Onikanni SA, da Cunha Goldstein A, et al. 3D bioprinted connections in Liver-Pancreas crosstalk: Lessons learned and future directions. Mol Cell Endocrinol. 2026;618:112806. doi: 10.1016/j.mce.2026.112806
- Ibrahim MS, Kim M. Artificial Intelligence-Aided Microfluidic Cell Culture Systems. Biosensors (Basel). 2025;16(1):16. doi: 10.3390/bios16010016
- Xie T, Huang A, Yan H, Ju X, Xiang L, Yuan J. Artificial intelligence: illuminating the depths of the tumor microenvironment. J Transl Med. 2024;22(1):799. doi: 10.1186/s12967-024-05609-6
- Lee JS, Cha JH, Kim BS. Artificial intelligence in 3D bioprinting and biofabrication: a validation-stringency assessment. Biofabrication. 2026;18(3):032003. doi: 10.1088/1758-5090/ae7b07
- Ashique S, Garg A, Islam A, et al. Exploring the role of 4D printing materials, techniques, and characteristics for personalized oncology. Transl Oncol. 2026;70:102818. doi: 10.1016/j.tranon.2026.102818
